SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Billie Holiday Synthetic CCD

PatientBillie Holiday
Date of birth1993-04-07
IdentifiersMRN HR-ML010-SYN; SSN (made up) 000-10-4472
Document date2026-11-01
AuthorConstance Mayfield, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Establishing primary care five weeks after release from custody: medication for opioid use disorder, overdose prevention, alcohol care, liver and infection screening, and depression and safety screening. Concerns: She wants to stay off heroin and keep singing, and is afraid of losing her tolerance and overdosing; She wants to drink less, especially around shows; She wants her records kept private and to be treated without judgment. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Buprenorphine 8 mg and naloxone 2 mg sublingual film: half a film (4 mg) on day 1, then one film (8 mg) under the tongue dailyOne film under the tongue daily after a 4 mg first doseSublingual route2026-04-20 to 2026-04-27completedS
Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once dailyTwo films under the tongue once dailySublingual route2026-04-27activeS
Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils; call 911One spray (4 mg) in one nostril for suspected overdose; repeat every 2 to 3 minutes if there is no responseNasal route2026-04-20activeS
Acamprosate 333 mg delayed-release oral tablet, two tablets (666 mg) by mouth three times dailyTwo tablets by mouth three times dailyOral route2026-04-27activeS
Thiamine 100 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-04-20 to 2026-10-19completedS
Amoxicillin 500 mg oral capsule, one capsule by mouth three times daily for seven daysOne capsule by mouth three times daily for seven daysOral route2026-09-21 to 2026-09-28completedS
Ibuprofen 400 mg oral tablet, one tablet by mouth every 6 to 8 hours with food as needed for tooth pain, for up to five daysOne tablet by mouth every 6 to 8 hours with food as needed, up to five daysOral route2026-09-21 to 2026-09-26completedS
Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for tooth pain, no more than 3,000 mg a day, for up to five daysTwo tablets by mouth every 8 hours as needed, up to 3,000 mg a dayOral route2026-09-21 to 2026-09-26completedS

Procedures

ProcedureDatesStatusEvidence
Advance care planning conversation, about 16 minutes2026-08-31 to 2026-08-31completedS

Immunizations

DateVaccineStatusEvidence
2026-04-20Tdap vaccinecompletedS
2026-04-20Hepatitis B vaccine (HepB-CpG), dose 1 of 2completedS
2026-04-20Hepatitis A vaccine, adult, dose 1 of 2completedS
2026-04-20Pneumococcal conjugate vaccine PCV20completedS
2026-05-26Hepatitis B vaccine (HepB-CpG), dose 2 of 2completedS
2026-10-19Hepatitis A vaccine, adult, dose 2 of 2completedS
2026-10-19Influenza vaccine, 2026-2027 seasoncompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
about 1943Heroin use from the early 1940s, becoming a severe addiction in the late 1940s; sought treatment for it at least onceD (CLM-0003, CLM-0005)
October 1945Heavier drinking and increased drug use after her mother's deathD (CLM-0002)
March 16, 1948Federal custody after a narcotics possession conviction, about ten months with enforced abstinence; released earlyD (CLM-0004)

Family History

RelativeConditionAge at deathEvidence
motherDied in 1945; cause not recorded in the cited sourceD (CLM-0002)

Health Concerns

ConcernStatusEvidence
She wants to stay off heroin and keep singing, and is afraid of losing her tolerance and overdosingactiveS
She wants to drink less, especially around showsactiveS
She wants her records kept private and to be treated without judgmentactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 12.9 on 2026-10-19; MCV [Entitic mean volume] in Red Blood Cells by Automated count 95 on 2026-10-19; Platelets [#/volume] in Blood by Automated count 248 on 2026-10-19; Sodium [Moles/volume] in Serum or Plasma 138 on 2026-04-20; Potassium [Moles/volume] in Serum or Plasma 4 on 2026-04-20; Creatinine [Mass/volume] in Serum or Plasma 0.72 on 2026-04-20; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 113 on 2026-04-20; Glucose [Mass/volume] in Serum or Plasma 88 on 2026-04-20; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 30 on 2026-10-19; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 26 on 2026-10-19; Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma 34 on 2026-10-19; Albumin [Mass/volume] in Serum or Plasma 4 on 2026-04-20; Bilirubin.total [Mass/volume] in Serum or Plasma 0.7 on 2026-04-20; Hepatitis C virus Ab Signal/Cutoff in Serum or Plasma by Immunoassay 0.09 on 2026-04-20; Hepatitis B virus surface Ab [Units/volume] in Serum 3 on 2026-04-20; Phosphatidylethanol [Mass/volume] in Blood 22 on 2026-10-19; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 2026-10-19; Total score [AUDIT-C] 3 on 2026-08-31; Total score [DAST-10] 7 on 2026-04-20 [S]

Strengths and supports: Supports: musicians she has worked with for years, a close friend who has agreed to carry naloxone, and a peer recovery coach; her music is her strongest source of purpose [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Opioid use disorder (heroin), severe; in early remission in a controlled environment at intake, five weeks after release from custody; on buprenorphine; synthetic modern episode linked to her documented heroin useactiveconfirmed F11.20S — Synthetic modern coding of the documented heroin addiction; language is person-first, and the code does not change with a return to use.
Alcohol use disorder, moderate; synthetic modern episode linked to her documented heavier drinking after her mother's deathactiveconfirmed F10.20S — Synthetic modern coding of the documented drinking; the liver disease reported in her last year is not coded, because it was documented long after the episode.
Acute periapical abscess of the lower right first molar with localized swelling, treated with an antibiotic and dental drainage; resolvedresolvedconfirmed K04.7S — Synthetic acute dental infection; not a historical claim.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-20Hemoglobin [Mass/volume] in Blood12.4g/dL11.6-15 g/dLNormalS
2026-04-20MCV [Entitic mean volume] in Red Blood Cells by Automated count101fL80-100 fLHighS
2026-04-20Platelets [#/volume] in Blood by Automated count23610*3/uL150-400 10*3/uLNormalS
2026-04-20Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
2026-04-20Potassium [Moles/volume] in Serum or Plasma4mmol/L3.5-5.1 mmol/LNormalS
2026-04-20Creatinine [Mass/volume] in Serum or Plasma0.72mg/dL0.59-1.04 mg/dLNormalS
2026-04-20Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M113mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-04-20Glucose [Mass/volume] in Serum or Plasma88mg/dL70-99 mg/dLNormalS
2026-04-20Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma52U/L10-40 U/LHighS
2026-04-20Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma38U/L7-56 U/LNormalS
2026-04-20Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma84U/L5-40 U/LHighS
2026-04-20Albumin [Mass/volume] in Serum or Plasma4g/dL3.5-5 g/dLNormalS
2026-04-20Bilirubin.total [Mass/volume] in Serum or Plasma0.7mg/dL0.1-1.2 mg/dLNormalS
2026-04-20Hepatitis C virus Ab Signal/Cutoff in Serum or Plasma by Immunoassay0.09{s_co_ratio}Below 1.00 is nonreactiveNormalS
2026-04-20Hepatitis B virus surface Ab [Units/volume] in Serum3m[IU]/mL>=10 m[IU]/mLLowS
2026-04-20Phosphatidylethanol [Mass/volume] in Blood312ng/mLBelow 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinkingHighS
2026-04-20Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]9{score}S
2026-04-20Total score [AUDIT-C]8{score}S
2026-04-20Total score [DAST-10]7{score}S
2026-05-26Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma38U/L10-40 U/LNormalS
2026-05-26Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma30U/L7-56 U/LNormalS
2026-05-26Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma52U/L5-40 U/LHighS
2026-05-26Phosphatidylethanol [Mass/volume] in Blood96ng/mLBelow 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinkingHighS
2026-05-26Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
2026-07-20Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma44U/L10-40 U/LHighS
2026-07-20Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma33U/L7-56 U/LNormalS
2026-07-20Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma61U/L5-40 U/LHighS
2026-07-20Phosphatidylethanol [Mass/volume] in Blood164ng/mLBelow 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinkingHighS
2026-07-20Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]11{score}S
2026-08-31Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
2026-08-31Total score [AUDIT-C]3{score}S
2026-10-19Hemoglobin [Mass/volume] in Blood12.9g/dL11.6-15 g/dLNormalS
2026-10-19MCV [Entitic mean volume] in Red Blood Cells by Automated count95fL80-100 fLNormalS
2026-10-19Platelets [#/volume] in Blood by Automated count24810*3/uL150-400 10*3/uLNormalS
2026-10-19Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma30U/L10-40 U/LNormalS
2026-10-19Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L7-56 U/LNormalS
2026-10-19Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma34U/L5-40 U/LNormalS
2026-10-19Phosphatidylethanol [Mass/volume] in Blood22ng/mLBelow 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinkingHighS
2026-10-19Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-04-20Body height165cmS
2026-04-20Body weight68kgS
2026-04-20Body mass index (BMI) [Ratio]25kg/m2S
2026-04-20Systolic blood pressure126mm[Hg]S
2026-04-20Diastolic blood pressure80mm[Hg]S
2026-04-20Heart rate84/minS
2026-04-20Respiratory rate16/minS
2026-04-20Body temperature36.8CelS
2026-04-20Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-04-27Body height165cmS
2026-04-27Body weight68.2kgS
2026-04-27Body mass index (BMI) [Ratio]25.1kg/m2S
2026-04-27Systolic blood pressure122mm[Hg]S
2026-04-27Diastolic blood pressure78mm[Hg]S
2026-04-27Heart rate78/minS
2026-04-27Respiratory rate14/minS
2026-04-27Body temperature36.7CelS
2026-04-27Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-05-26Body height165cmS
2026-05-26Body weight68.6kgS
2026-05-26Body mass index (BMI) [Ratio]25.2kg/m2S
2026-05-26Systolic blood pressure118mm[Hg]S
2026-05-26Diastolic blood pressure76mm[Hg]S
2026-05-26Heart rate74/minS
2026-05-26Respiratory rate14/minS
2026-05-26Body temperature36.6CelS
2026-05-26Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-07-20Body height165cmS
2026-07-20Body weight67.4kgS
2026-07-20Body mass index (BMI) [Ratio]24.8kg/m2S
2026-07-20Systolic blood pressure128mm[Hg]S
2026-07-20Diastolic blood pressure82mm[Hg]S
2026-07-20Heart rate86/minS
2026-07-20Respiratory rate16/minS
2026-07-20Body temperature36.8CelS
2026-07-20Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-10-19Body height165cmS
2026-10-19Body weight69kgS
2026-10-19Body mass index (BMI) [Ratio]25.3kg/m2S
2026-10-19Systolic blood pressure116mm[Hg]S
2026-10-19Diastolic blood pressure74mm[Hg]S
2026-10-19Heart rate72/minS
2026-10-19Respiratory rate14/minS
2026-10-19Body temperature36.6CelS
2026-10-19Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-08-31Body height165cmS
2026-08-31Body weight68.8kgS
2026-08-31Body mass index (BMI) [Ratio]25.3kg/m2S
2026-08-31Systolic blood pressure118mm[Hg]S
2026-08-31Diastolic blood pressure76mm[Hg]S
2026-08-31Heart rate74/minS
2026-08-31Respiratory rate14/minS
2026-08-31Body temperature36.7CelS
2026-08-31Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-09-21Body height165cmS
2026-09-21Body weight68.4kgS
2026-09-21Body mass index (BMI) [Ratio]25.1kg/m2S
2026-09-21Systolic blood pressure130mm[Hg]S
2026-09-21Diastolic blood pressure82mm[Hg]S
2026-09-21Heart rate92/minS
2026-09-21Respiratory rate16/minS
2026-09-21Body temperature37.6CelS
2026-09-21Oxygen saturation in Arterial blood by Pulse oximetry99%S

Encounters

DatePurposeStatusProvenance
2026-04-20Establishing primary care five weeks after release from custody: medication for opioid use disorder, overdose prevention, alcohol care, liver and infection screening, and depression and safety screeningfinishedS
2026-04-27One-week buprenorphine check and addiction medicine consultationfinishedS
2026-05-26Five-week recovery review and second hepatitis B vaccinefinishedS
2026-07-20Three-month review after a return to opioid use: adjusting the recovery planfinishedS
2026-10-19Six-month recovery, alcohol, liver, and mood reviewfinishedS
2026-08-31Periodic adult preventive visitfinishedS
2026-09-21Same-day sick visit for a dental abscessfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Buprenorphine with naloxone started in primary care at a low first dose, then 16 mg daily, continued through any return to use; naloxone, overdose education, never using alone, and fentanyl test stripscompletedGL-ASAM-OUD-2020, GL-SAMHSA-MOUD, GL-SUD-2021S
Addiction medicine consultation to confirm the medication plan, choose a medicine for alcohol use disorder that can be used with buprenorphine, and set the monitoring plancompletedGL-ASAM-OUD-2020, GL-SUD-2021S
Alcohol care: acamprosate, thiamine, brief counseling and goals she chooses, and PEth at each check to follow drinking without relying on memorycompletedGL-SUD-2021, GL-SAMHSA-MOUDS
Liver and infection screening: liver tests and FIB-4 at intake and six months, hepatitis C antibody, hepatitis B triple panel, and HIV test, with hepatitis A and B vaccines for a person who is not immunecompletedGL-AASLD-ALD-2019, GL-AASLD-NIT-2025, GL-CDC-HBV-2023, GL-USPSTF-HCV-2020, GL-USPSTF-HIV-2019S
Depression screening with the PHQ-9 at each recovery visit, a structured safety assessment with a written safety plan and the 988 Suicide & Crisis Lifeline, and safety review at every visitcompletedGL-CMID-2026, GL-USPSTF-DEP-2023, GL-SUICIDE-2024S
Integrated, trauma-informed recovery plan: weekly counseling, a peer recovery coach, confidentiality she controls, and a written plan for touring, without requiring recovery to be perfect or linearcompletedGL-SUD-2021, GL-SAMHSA-MOUDS

Goals

GoalTargetStatusOutcomeProvenance
Stay on buprenorphine without interruption through six months, including through any return to use2026-10-19completedTaking buprenorphine 16 mg daily at six months; a three-day gap during a tour was followed by a brief return to use and an immediate restart, with no overdoseS
Naloxone at home and in her bag, and a friend trained to use it, by the one-week visit2026-04-27completedTwo naloxone two-packs dispensed; her friend trainedS
Reduce drinking to PEth below 20 ng/mL, or to the level she chooses, by six months2026-10-19completedPEth 22 ng/mL from 312; occasional light drinking, which she choseS
Hepatitis A and B vaccine series completed by six months2026-10-19completedHepatitis B doses at intake and five weeks; hepatitis A doses at intake and six monthsS
PHQ-9 score below 5 by six months2026-10-19completedPHQ-9 4S

Functional Status

Mental Status

Structured synthetic safety assessment on 2026-04-20: current ideation absent, intent absent, plan absent. Outpatient care. Overdose risk is high in the weeks after release because tolerance has fallen: naloxone for her and her friend, never using alone, testing any drug supply with fentanyl test strips, and buprenorphine started today. The 988 Suicide & Crisis Lifeline was given and saved in her phone, and a written safety plan was made with her. Safety reviewed at every visit [S]